Celldex brain cancer vaccine doubles survival

	Tweet

Patients with the brain cancer glioblastoma treated with a vaccine lived nearly twice as long as those who received radiation and chemotherapy, an encouraging result for a cancer that often kills patients within a year, U.S. researchers said on Monday.

The Celldex Therapeutics Inc vaccine works by targeting a mutation in a gene called the epidermal growth factor receptor, which fuels cancer growth.

“It does appear to help patients live much longer than we could have expected,” said Dr. John Sampson of Duke University in North Carolina, whose team worked on the study published in the Journal of Clinical Oncology.

Working with researchers at The University of Texas MD Anderson Cancer Center, Sampson’s team showed the vaccine killed cancer cells carrying the mutation in all but one patient.

Immune response tests showed patients who developed antibodies after being vaccinated were most likely to respond, giving doctors a good way to see which patients might benefit, Sampson said in a telephone interview.

He said many patients in the study are still alive after five years. “That is pretty unusual with this disease.”

Glioblastoma multiforme typically kills half its victims within a year and patients rarely survive more than three years. Sampson remains cautious and says the treatment still needs to be proven in a large-scale clinical trial.

CANCER IMMUNOTHERAPY

The finding is yet another example of the potential of cancer immunotherapies - treatments that recruit the immune system to fight cancer.

Earlier this year, the U.S. Food and Drug Administration approved the first cancer vaccine, Dendreon Corp’s prostate cancer therapy Provenge.

And a team in June said Bristol-Myers Squibb Co’s immune system treatment ipilimumab helped extend the lives of patients with aggressive melanoma, the deadliest form of skin cancer for which there are few treatment options.

For the midstage brain cancer study, researchers enrolled 35 people with glioblastoma who had undergone radiation and were treated with the chemotherapy drug temozolomide, sold by Merck under the brand name Temodar, which is thought to boost immune response.

Of those, 18 people got the vaccine and 17 were in a control group. Those who got the vaccine lived an average of 26 months, compared with 15 months for those in the control arm.

Sampson said the vaccine is the first to target proteins only present in cancer cells, which could mean it would have fewer side effects than other cancer vaccines.

He said he has no current financial ties to Celldex, but has received research funding from the company in the past.

Epidermal growth factor receptor mutations are found in many other cancers, and the teams say the vaccine should be tested in other cancers as well. But funding the large studies it will take to prove the vaccine works may be a challenge.

Last month, Celldex’s partner Pfizer Inc pulled out of a strategic partnership to develop the vaccine, and the company said it now plans to develop it on its own.

The National Cancer Institute is spending $14 million over five years to develop a network of clinics to test cancer immunotherapy treatments.

SOURCE:  Journal of Clinical Oncology, online October 4, 2010.

RELATED STORIES:
Brain tumors: New therapy surprisingly successful   Robotic Surgery for Head and Neck Cancer Shows Promise   New treatment combination proves safe, effective for head and neck cancer patients   Target for Therapeutic Drugs to Fight Most Common Adult Brain Cancer   Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer   WHO study has no clear answer on phones and cancer   Genetics of children’s brain tumour unlocked   Potential for non-invasive brain tumor treatment   Blood Pressure Compound May Benefit Brain Tumor Patients   Variations in Five Genes Raise Risk for Most Common Brain Tumors   Protein Aurora-A is found to be associated with survival in head and neck cancer   Early morning smokers have increased risk of lung and head and neck cancers   Does Green Tea Prevent Cancer? Evidence Continues to Brew, But Questions Remain   Brain Cancer Experts and Resources at Johns Hopkins   Quality of life after treatment for head and neck cancer associated with longer-term survival   Researchers Discover Non-Surgical Test for Brain Cancer   New way to identify patients at risk of dysphagia after head and neck cancer treatment   Prenatal Vitamins May Reduce Risk of Brain Tumors in Children   New robotic head and neck cancer surgery preserves speech, without scarring   IMRT improves outcomes in patients with extranodal lymphoma of the head and neck   Cancer Researcher Offer New Hope for Brain Tumor   Signaling System Found that Halts the Growth of a Childhood Brain Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]